Barclays Maintains Overweight on Oscar Health, Raises Price Target to $39

Benzinga Newsdesk www.benzinga.com Positive 66.2%

Neg 0% Neu 0% Pos 66.2%

Barclays analyst Andrew Mok maintains Oscar Health (NYSE:OSCR) with a Overweight and raises the price target from $35 to $39.